PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (OTC Market:AVXT.OB) announces that its abstract, entitled, “Dose-response study of a cryopreserved, autologous, hapten-modified melanoma vaccine (MVax®),” has been accepted for presentation at the annual meeting of the American Society for Clinical Oncology (ASCO) to be held May 30-June 3 in Chicago. The abstract was selected from the over 4,800 that were reviewed by ASCO’s Scientific Program Committee this year.
